Relvar Ellipta 200/25 Bột hít phân liều

国: ベトナム

言語: ベトナム語

ソース: BỘ Y TẾ (CỤC QUẢN LÝ DƯỢC)

有効成分:

Fluticasone furoate; Vilanterol (dưới dạng Vilanterol trifenatate)

から入手可能:

GlaxoSmithKline Pte., Ltd.

INN（国際名）:

Fluticasone furoate; Vilanterol (as Vilanterol trifenatate)

投薬量:

200mcg/1 liều chưa phóng thích; 25mcg/1 liều chưa phóng thích

医薬品形態:

Bột hít phân liều

パッケージ内のユニット:

Hộp chứa 1 dụng cụ 30 liều hít

クラス:

Thuốc kê đơn

製:

Glaxo Operations UK Ltd. (trading as Glaxo Wellcome Operations)

製品概要:

Tiêu Chuẩn: NSX; Tuổi Thọ: 24 tháng; Tá dược: Lactose monohydrate (chứa protein sữa); magnesi stearate

情報リーフレット

i
l
xfzs
L
P4v1c
^^sl
Sticker
of
I
ql
PI
I
z
//i)
5
a
o
*
vAr,r
pub
oer
olEru
lRr
r.p
nA
NG
porterrO
v
rd
cUc
quaiv
uf
nr-roc
PHE
X}UYET
.IJ6.
DNNK:
Carton
PTE
*
I
z
o
br'1
-\
,i
(!
dt
EN
c
l!
o
=
E
E
o
@
d
c
o
E
o
o
6
a
o
=
o
c
E
!
o
(,
o
E
E
o
o
'=
e
o
o
I
F
o
z
6
E
c
o
E
,
o
!
.9
t
z
-
F
E
5
o
!
.!
c
o
6
o
d
e
o
F
o
z
o
6
o
c
a
o
c
.9
E
c
=
,
o
,9
e
2
i,
c
.e
This
PDF
has
been
ve
rified
using
PitStop
12
PDF is
PDF/X4
comoliant
and
GSK comrrliant
for
Cartons
backino
cards
workflow
Body
text
size:
N/A
Smallest
text
size: N/A
Microtext:
No
TEXT SIZE
CONTAINED IN THIS ARTWORK
GlaxoSmithKline
Artwork
lnformation
Panel
VAN
PHONG
DAI
DIEN
TAI T.P
HA
ruol
GSK
Market
is
responsible
for
this
product,
its
design and
content.
Ensure
the
artwork
is
thoroughly
checked,
all
the
text
proof-read
and
approved.
RSC
GSK
is
responsible
for
site technical
requirements and
pre-press
stuitability.
\
Item
Number:
10000000133677
Manufacturing
Site:
GSK-GBR-Ware-UKWAR
Market
or
Pack
Owner:
Vietnam-VNM
Market
Trade
Name:
Relvar
Ellipta
Colour Standard
Reference
Number:
N/A
(do
NOT
indude
tha
teahni6l
reference
dfilsl
veraion
nolsl.)
Technical Reference
No(s).:
JHA2301
Printing
Process:
N/A
Substrate:
N/A
Total:
5
Tota!:
1
Total:0
Artwork
copright
is
the
property
of
the
GlaxosmithKline
6roup of
Companies
All
suppliers
providing
a serui(e
to
GsK
for
printed
components
of
any
description
must ensure
that
they
have a licence
for
all fonts / software
used
in
conjunction
with
GSK
artwork.
The
distribution
and
use
of
fonts
/
software
without
a licence
(onstitutes
an intellectual
property
infringement.
GSK
will not
a((ept any
liability
for
the
breach
of
third
party
intellectual
property
rights
by
printed
component
suppliers.
The
GSK
(ertifi(ation
/
audit
pro(ess
requires
suppliers
to
de(lare
that
they do
not
use unlicensed
fontr
/
software and
may
require the supplier
to
produ(e
evidence
of
such
li(ence
to
GSK.
Formulation,
Tablet
embossing, Storage
conditions,
SpecialFinishes
288
2905
233
Varnishes
lf
Life
IMPORTANT
2
Colours
K
ffi
GSK
Market
i